Sage Therapeutics in Phase 2 for Huntington’s Disease Drug SAGE-718

Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 15, 2021– Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington’s disease (HD). Fast Track is a process designed to facilitate the development and review of new treatments for serious conditions with unmet medical need such as Huntington’s Disease (HD).

“Sage is working to understand the underlying reasons for disorders of the brain and central nervous system (CNS). We hope this science will help us develop potential therapies that may address treatment gaps for patients with brain health disorders.

Sage is exploring SAGE-718 in neurodegenerative disorders like Huntington’s Disease, Alzheimer’s Disease, and Parkinson’s Disease. Ongoing studies aim to evaluate whether SAGE-718 may have the potential to improve cognitive and/or behavioral symptoms for these difficult-to-treat disorders.

We are using our unique development approach to systemically evaluate our drug candidates in a range of neuropsychiatric disorders associated with cognitive impairment, including:

Read full article here

We Can Never Lose HOPE……